Physician profile
Kurt E Johnson
NPI 1407881741
$22,468.98
in general payments reported to CMS, 2019-2025
75 companies · $2,719 in 2025
The $2,719 reported for 2025 was more than what 98% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,909 · 2020: $3,302 · 2021: $3,872 · 2022: $2,895 · 2023: $2,873 · 2024: $2,900 · 2025: $2,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,491.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,382.24 | 2019-2025 | |
| Amgen INC. | $2,512.39 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $2,272.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,751.24 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,317.14 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $1,030.62 | 2019-2025 | Farxiga, Airsupra, Evusheld |
| Janssen Pharmaceuticals, INC | $945.47 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $868.59 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $807.43 | 2019-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $713.84 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $555.12 | 2019-2020 | |
| Corcept Therapeutics | $534.86 | 2019-2025 | Korlym |
| Merck Sharp & Dohme LLC | $523.09 | 2019-2025 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Amarin Pharma, INC. | $498.18 | 2019-2021 | |
| Daiichi Sankyo INC. | $368.01 | 2019-2025 | Injectafer |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.